These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 18435363)

  • 1. Conversion from epoetin alfa to darbepoetin alfa within the Manitoba Renal Program: evaluation of dose ratios.
    Raymond CB; Wazny LD; Vercaigne LM; Lesperance EM; Skwarchuk DE; Bernstein KN
    CANNT J; 2008; 18(1):39-43. PubMed ID: 18435363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA; Walker R;
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population.
    Sharma A; Yee J; Gandra SR; Khan I; Petersen J
    Curr Med Res Opin; 2010 Nov; 26(11):2679-87. PubMed ID: 20942616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
    Hoggard J; Crouch T; McMurray S; Levine M; Prathikanti R; Scarlata D; Audhya P
    Curr Med Res Opin; 2006 Oct; 22(10):2023-30. PubMed ID: 17022861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
    Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials?
    Roger SD; Cooper B
    Nephrology (Carlton); 2004 Aug; 9(4):223-8. PubMed ID: 15363054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease.
    Joy MS; Candiani C; Vaillancourt BA; Chin H; Hogan SL; Falk RJ
    Pharmacotherapy; 2007 May; 27(5):734-44. PubMed ID: 17461709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
    Mahajan S; Boulton H; Gokal R
    J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.
    Duh MS; Mody SH; Scott McKenzie R; Lefebvre P; Gosselin A; Tak Piech C
    Clin Ther; 2006 Sep; 28(9):1443-50. PubMed ID: 17062316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease.
    Horowitz J; Agarwal A; Huang F; Gitlin M; Gandra SR; Cangialose CB
    J Manag Care Pharm; 2009; 15(9):741-50. PubMed ID: 19954265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
    Fischbach M; Wühl E; Reigner SCM; Morgan Z; Schaefer F
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):81-90. PubMed ID: 29097481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Resistance index to epoetin alpha and to darbepoetin-alpha in chronic hemodialysis patients: a cohort study].
    Pérez-García R; Rodríguez Benítez P; Jofre R; López-Gómez JM; Villaverde MT; Blanco A; Blanco S; Sánchez M
    Nefrologia; 2007; 27(3):340-9. PubMed ID: 17725454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
    Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switch of ESA therapy from darbepoetin-alpha to epoetin-beta in hemodialysis patients: a single-center experience.
    Biggar P; Ketteler M; Hennemann H; Dömling R
    Clin Nephrol; 2008 Mar; 69(3):185-92. PubMed ID: 18397717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies.
    Scott SD
    Pharmacotherapy; 2002 Sep; 22(9 Pt 2):160S-165S. PubMed ID: 12222586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes associated with conversion from epoetin alfa to darbepoetin alfa in hospitalized hemodialysis patients.
    Sarac E; Chikyarappa A; Sabol B; Gemmel D; Globe D; Barlev A; Audhya P
    Am J Nephrol; 2006; 26(6):571-8. PubMed ID: 17170523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switch From Epoetin Beta to Darbepoetin Alfa Treatment of Anemia in Taiwanese Hemodialysis Patients: Dose Equivalence by Hemoglobin Stratification.
    Liao SC; Hung CC; Lee CT; Lee CH; Lee CC; Lin CL; Sun CY; Cheng BC; Yang CC; Wu CH; Chen JB
    Ther Apher Dial; 2016 Aug; 20(4):400-7. PubMed ID: 27060362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
    Kessler M; Hannedouche T; Fitte H; Cayotte JL; Urena P; Réglier JC;
    Nephrol Ther; 2006 Sep; 2(4):191-9. PubMed ID: 16966064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term intravenous epoetin-alpha / darbepoetin-alpha ratio in iron-replete hemodialysis patients.
    Icardi A; Sacco P; Salvatore F; Romano U
    J Nephrol; 2007; 20(1):73-9. PubMed ID: 17347977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
    Nurko S; Spirko R; Law A; Dennis VW
    Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.